Regulation of VEGF-A in Uveal Melanoma

被引:56
作者
el Filali, Mariam [1 ]
Missotten, Guy S. O. A. [1 ]
Maat, Willem [1 ]
Ly, Long V. [1 ]
Luyten, Gregorius P. M. [1 ]
van der Velden, Pieter A. [1 ]
Jager, Martine J. [1 ]
机构
[1] LUMC, Dept Ophthalmol, NL-2300 RC Leiden, Netherlands
关键词
ENDOTHELIAL-GROWTH-FACTOR; PERMEABILITY FACTOR EXPRESSION; TUMOR ANGIOGENESIS; SURVIVAL; SERUM; ESTABLISHMENT; XENOGRAFTS; VARIABLES; PATHWAYS; DENSITY;
D O I
10.1167/iovs.09-4739
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. Blood vessels are important constituents of intraocular uveal melanoma (UM), but whether angiogenesis is regulated by environmental factors such as ischemia or by genetic mechanisms is not known. This study was undertaken to examine the regulation of the proangiogenic factor vascular endothelial growth factor (VEGF-A). METHODS. Cell lines and primary tumors were tested for expression of VEGF-A, under normoxic and hypoxic conditions, using quantitative PCR, ELISA, WST-1 viability, and in-cell Western experiments. VEGF-A serum levels were determined by ELISA. RESULTS. Hypoxia induced expression of HIF-1 alpha and VEGF-A in UM cell lines and primary tumor cultures, but it did not influence proliferation. VEGF-A expression in primary tumors was variable, demonstrating no correlation with specific histologic markers or prognosis. However, VEGF-A levels were significantly raised in UM patients with metastases compared with those without metastases (P < 0.001). CONCLUSIONS. VEGF-A expression by UM cells is mainly controlled by hypoxia and involves the HIF-1 alpha pathway, thus indicating an important role for the tumor cell environment. Metastases led to increased serum VEGF-A levels, indicating that VEGF-A may be involved in the growth of metastases. (Invest Ophthalmol Vis Sci. 2010;51:2329-2337) DOI: 10.1167/iovs.09-4739
引用
收藏
页码:2329 / 2337
页数:9
相关论文
共 45 条
[1]   Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy [J].
Augsburger, JJ ;
Corrêa, ZM ;
Freire, J ;
Brady, LW .
OPHTHALMOLOGY, 1998, 105 (09) :1670-1678
[2]  
BARAK V, 2009, INT C OC ONC CAMBR U
[3]  
Barak V, 2007, ANTICANCER RES, V27, P1897
[4]   Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 [J].
Barleon, B ;
Sozzani, S ;
Zhou, D ;
Weich, HA ;
Mantovani, A ;
Marme, D .
BLOOD, 1996, 87 (08) :3336-3343
[5]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[6]   Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window [J].
Boyd, SR ;
Tan, D ;
Bunce, C ;
Gittos, A ;
Neale, MH ;
Hungerford, JL ;
Charnock-Jones, S ;
Cree, IA .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2002, 86 (04) :448-452
[7]   Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays [J].
Bustin, SA .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2000, 25 (02) :169-193
[8]  
Celen O, 2004, NEOPLASMA, V51, P293
[9]   A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy [J].
Chen, HX ;
Kovar, J ;
Sissons, S ;
Cox, K ;
Matter, W ;
Chadwell, F ;
Luan, P ;
Vlahos, CJ ;
Schutz-Geschwender, A ;
Olive, DM .
ANALYTICAL BIOCHEMISTRY, 2005, 338 (01) :136-142
[10]   Expression of MAGE genes in ocular melanoma cell lines [J].
Chen, PW ;
Murray, TG ;
Salgaller, ML ;
Ksander, BR .
JOURNAL OF IMMUNOTHERAPY, 1997, 20 (04) :265-275